Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

High-Throughput Screening for Kinase Inhibitors

By Drug Discovery Trends Editor | May 12, 2008

Free Webcast on Demand

High-Throughput Screening (HTS) for Kinase Inhibitors

Who Likes Kinases?

 

 

 

 

 

How are leading Pharma researchers using HTS to identify kinase inhibitors? Protein kinases play crucial roles in biological processes and aberrant kinase activity in human disease including cancer and autoimmune diseases. View an in-depth discussion with leading Pharma researchers who are targeting kinases for the development of new drugs.

Moderator:
James Netterwald, PhD, MT (ASCP)
Senior Editor
Drug Discovery & Development

Panelists:
Kirk McMillan, PhD
Vice President, Lead Discovery
Exelixis, Inc.

Kim Arndt, PhD
Senior Director, Oncology
Wyeth Research

Pirthipal Singh
Associate Principal Scientist; DECS-LG
AstraZeneca

  • Protein kinases account for 25% to 30% of all targets screened in the pharmaceutical industry today.  Which targets offer the most potential?
  • Fast, reliable, high-throughput screening methods are necessary to determine which potential kinase inhibitors are worthy of further clinical development and which are not.  Which processes work best?
  • Screening platforms based on a variety of different technologies are currently available, but all of them have inherent technical challenges that can affect results; this Webcast will discuss some of the challenges.
  • This informative Webcast covers this popular research strategy and everything you need to know about the latest discoveries, challenges, and trends in kinase inhibitor research and HTS.

View this free event on demand now!


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50